Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Seattle gets orphan status for two cancer drugs
Seattle Genetics expects that SGN-33, the candidate for acute myeloid leukemia (AML) patients, will be advanced into two combination clinical trials during 2007. This will include a phase
Seattle Genetics expects that SGN-33, the candidate for acute myeloid leukemia (AML) patients, will be advanced into two combination clinical trials during 2007. This will include a phase
Boehringer Ingelheim will apply Xencor's proprietary XmAb technology platform, including proprietary Fc domains, to maximize the efficacy of its antibody drug candidates against selected targets of interest. Xencor's
This is the second of several phase I studies to be conducted in order to evaluate the safety and initial efficacy of the candidate R763 in different types
Under the terms of the alliance agreement, Pharmacopeia will receive an up-front payment of $15 million and additional payments in research funding over the five-year term of the
This patent had originally been scheduled to expire in April 2010. Following this five year term extension, the patent will now expire in April 2015. Aloxi is approved
Accelerated reviews are granted to potential medicines that would represent significant improvements over current therapies. If approved by the regulatory agencies, maraviroc will be the first in a
LymphoStat-B is being developed by the companies under a definitive development and commercialization agreement entered into in August 2006. The program includes two phase III superiority trials to
“The introduction of atorvastatin in Denmark is a significant milestone in Ranbaxy's atorvastatin strategy and heralds the beginning of the company's determined efforts to bring affordable atorvastatin to
The WHO prequalification endorses the vaccine's quality, safety and efficacy, and its ability to fulfill tender specifications. This allows UN agencies, such as the Pan American Health Organization
Sanofi said it had expected the decision by April 26. Last week an independent advisory committee in France endorsed the drug for reimbursement by health insurance companies and